Pharvaris Confirms H1 2026 NDA Submission for HAE Treatment, Details 2025 Financials and Recent $124M Capital Raise
PHVS has more than doubled off its 52-week low of $16 on light trading volume (0.4× avg).
Summary
Pharvaris N.V. announced its Annual General Meeting and furnished its 2025 Annual Report, detailing increased R&D expenses, a €175.7 million net loss, and a strong cash position of €291.7 million, bolstered by a recent $124.3 million public offering. The company confirmed its plan to submit an NDA for its on-demand HAE treatment in H1 2026 and provided updates on ongoing pivotal Phase 3 studies.
Key Events · Product Development and Regulatory · PHVS
-
Annual General Meeting Scheduled
Pharvaris N.V. announced its 2026 Annual General Meeting of Shareholders for June 26, 2026, with an agenda including the adoption of 2025 annual accounts and a proposal to renew the Board's share repurchase authorization.
-
2025 Financial Overview
The company reported a net loss of €175.7 million for 2025, an increase from €134.2 million in 2024, primarily due to a 26% rise in R&D expenses to €124.5 million as it advanced its Phase 3 clinical programs.
-
Strengthened Cash Position
As of December 31, 2025, cash and cash equivalents totaled €291.7 million. This was significantly augmented by a $124.3 million net proceeds public offering that closed on May 11, 2026, extending the company's cash runway into 2028.
-
HAE Treatment NDA Submission on Track
Following positive pivotal Phase 3 data for its on-demand HAE treatment (RAPIDe-3) in December 2025, Pharvaris confirmed its plan to submit a New Drug Application (NDA) to the FDA in the first half of 2026.
Analysis · PHVS · Life Sciences
This 6-K filing, which includes the 2025 Annual Report, provides a comprehensive update on Pharvaris N.V.'s financial health and significant progress in its clinical pipeline. The increased net loss is typical for a late-stage biopharmaceutical company heavily investing in R&D, which is evident from the 26% rise in R&D expenses. The successful $124.3 million public offering, confirmed as a material subsequent event, significantly bolsters the company's cash position, extending its operational runway and providing crucial funding for its ongoing and planned clinical programs. The positive pivotal Phase 3 data for the on-demand HAE treatment (RAPIDe-3) and the confirmed H1 2026 NDA submission timeline are major milestones that could lead to market approval and future revenue generation. Additionally, the ongoing Phase 3 studies for prophylactic HAE (CHAPTER-3) and AAE-C1INH (CREAATE) demonstrate continued pipeline advancement. The company's stock trading near its 52-week high reflects investor confidence in these developments.
At the time of this filing, PHVS was trading at $32.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.00 to $33.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.